Susquehanna International Group’s Bicycle Therapeutics BCYC Stock Holding History

Susquehanna International Group’s Portfolio BCYC Stock Details BCYC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$176K	Sell	37,888 -70,535	-65%	-$403K	﹤0.01%	11829
2025 Q4	$768K	Buy	108,423 +81,794	+307%	+$603K	﹤0.01%	7794
2025 Q3	$206K	Buy	26,629 +62	+0.2%	+$468	﹤0.01%	10933
2025 Q2	$185K	Buy	+26,567	New	+$212K	﹤0.01%	11292
2024 Q1	–	Sell	-24,535	Closed	-$521K	–	12168
2023 Q4	$444K	Sell	24,535 -41,146	-63%	-$681K	﹤0.01%	8967
2023 Q3	$1.32M	Buy	65,681 +3,017	+5%	+$69K	﹤0.01%	6007
2023 Q2	$1.6M	Buy	62,664 +18,091	+41%	+$420K	﹤0.01%	5620
2023 Q1	$948K	Buy	44,573 +7,518	+20%	+$189K	﹤0.01%	6968
2022 Q4	$1.1M	Buy	+37,055	New	+$994K	﹤0.01%	5978
2021 Q4	–	Sell	-18,475	Closed	-$1.02M	–	13102
2021 Q3	$768K	Buy	+18,475	New	+$646K	﹤0.01%	8242

Other funds holding BCYC

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

FIS

FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

LFCM

Long Focus Capital Management San Juan, Puerto Rico $3.8B AUM 7.31% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

GSK plc London $599M AUM

Principal Financial Group Des Moines, Iowa $187B AUM 18.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Susquehanna International Group's BCYC Position: Q1 2026 in Review

Susquehanna International Group reduced its Bicycle Therapeutics (BCYC) stake by 65% in Q1 2026, selling an estimated $403K and leaving 37,888 shares worth $176K. The position accounts for ﹤0.01% of the portfolio, ranked #11829.

Susquehanna International Group first reported a position in BCYC in Q3 2021 and has held it in 10 quarters since. The position peaked at $1.6M in Q2 2023. 98 funds tracked by Wall St. Rank hold BCYC as of Q1 2026.

Susquehanna International Group held 37,888 shares of Bicycle Therapeutics worth $176K as of Q1 2026.
Susquehanna International Group sold 70,535 Bicycle Therapeutics shares in Q1 2026, an estimated $403K.
Bicycle Therapeutics made up ﹤0.01% of Susquehanna International Group's portfolio in Q1 2026, its #11829 holding.
Susquehanna International Group first reported a position in Bicycle Therapeutics in Q3 2021 and has held it in 10 quarters since.
Susquehanna International Group's Bicycle Therapeutics position peaked at $1.6M in Q2 2023.
98 funds tracked by Wall St. Rank held Bicycle Therapeutics as of Q1 2026.

Based on Susquehanna International Group's 13F filing for Q1 2026, filed 15 May 2026.